Search - tctmd.com

Displaying 41 - 60 of 3208

Sort: Relevancy | Date

News Conference News AHA 2016

Shaky FUTURE? FFR Takes a Hit With Mortality Signal in French Study

Michael O'Riordan

November 14, 2016

News Conference News AHA 2016

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

Todd Neale

November 14, 2016

News Conference News AHA 2016

Secondhand Smoke Exposure Associated With Increased Risk of Coronary Atherosclerosis

Michael O'Riordan

November 13, 2016

News Daily News

登记表数据显示原发性 PCI 患者比伐卢定与肝素使用率波动

Yael L. Maxwell

November 11, 2016

News Daily News

Registry Data Show Rise and Fall of Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

November 11, 2016

News Daily News

Datos de Registro Revelan el Ascenso y Caída de la Bivalirudina frente a la Heparina en la Realización de PCI Primarias

Yael L. Maxwell

November 11, 2016

News Daily News

Periprocedural MI Predicts Mortality After PCI for Chronic Total Occlusion

L.A. McKeown

November 10, 2016

News Daily News

MILANO-PILOT Falters, Effectively Ending the ApoA-1 Milano Saga

Michael O'Riordan

November 09, 2016

News Conference News TCT 2016

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

Shelley Wood

November 07, 2016

News Conference News TCT 2016

TRANSFORM-OCT: 生物可吸收和耐久聚合物 DES 早期和晚期愈合率类似

Michael O'Riordan

November 02, 2016

News Conference News TCT 2016

TRANSFORM-OCT: Similar Early and Late Healing With Bioresorbable- and Durable-Polymer DES

Michael O'Riordan

November 02, 2016

News Conference News TCT 2016

TRANSFORM-OCT: Similar Curación Precoz y Tardía con SLF Bioreabsorbibles y de Polímero Duradero

Michael O'Riordan

November 02, 2016

Presentation TCT 2016

Is Ablation an Alternative to Triple Therapy in Patients With Atrial Fibrillation and PCI or ACS?

Presenter: Martin W. Bergmann, Samir R. Kapadia, Vivek Y. Reddy

November 01, 2016

Presentation TCT 2016

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Presenter: Martin W. Bergmann, Samir R. Kapadia, Harvey D. White

November 01, 2016

Presentation TCT 2016

Case Conclusion: How Did We Treat Our Patient?

Presenter: George D. Dangas, Fabio Felice Tarantino, Massimo Fineschi

November 01, 2016

Presentation TCT 2016

Selecting the Right LAA Closure Device Based on Patient Characteristics and LAA Anatomy: Occluder, Ligation, or Clipping

Presenter: Martin W. Bergmann, Samir R. Kapadia, Jason H. Rogers

November 01, 2016

Presentation TCT 2016

Is LAA Closure an Alternative to Triple Therapy for all Patients or Those at High Bleeding Risk? Current Dataset

Presenter: Martin W. Bergmann, Samir R. Kapadia, Brian K. Whisenant

November 01, 2016

Presentation TCT 2016

Case Introduction: What Device(s) to Choose in a Patient With NSTE-ACS?

Presenter: George D. Dangas, Fabio Felice Tarantino, Massimo Fineschi

November 01, 2016

Presentation TCT 2016

Why Triple Therapy? Rationale and Potential Role for LAA Closure in the PCI Patient

Presenter: Martin W. Bergmann, Samir R. Kapadia, Ashish Pershad

November 01, 2016

Presentation TCT 2016

Case Conclusion: How Did We Treat Our Patient?

Presenter: Roxana Mehran, Ferdinando Varbella, Alberto Menozzi

November 01, 2016

Advertisement

Shaky FUTURE? FFR Takes a Hit With Mortality Signal in French Study

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

Secondhand Smoke Exposure Associated With Increased Risk of Coronary Atherosclerosis

登记表数据显示原发性 PCI 患者比伐卢定与肝素使用率波动

Registry Data Show Rise and Fall of Bivalirudin vs Heparin for Primary PCI

Datos de Registro Revelan el Ascenso y Caída de la Bivalirudina frente a la Heparina en la Realización de PCI Primarias

Periprocedural MI Predicts Mortality After PCI for Chronic Total Occlusion

MILANO-PILOT Falters, Effectively Ending the ApoA-1 Milano Saga

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

TRANSFORM-OCT: 生物可吸收和耐久聚合物 DES 早期和晚期愈合率类似

TRANSFORM-OCT: Similar Early and Late Healing With Bioresorbable- and Durable-Polymer DES

TRANSFORM-OCT: Similar Curación Precoz y Tardía con SLF Bioreabsorbibles y de Polímero Duradero

Is Ablation an Alternative to Triple Therapy in Patients With Atrial Fibrillation and PCI or ACS?

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Case Conclusion: How Did We Treat Our Patient?

Selecting the Right LAA Closure Device Based on Patient Characteristics and LAA Anatomy: Occluder, Ligation, or Clipping

Is LAA Closure an Alternative to Triple Therapy for all Patients or Those at High Bleeding Risk? Current Dataset

Case Introduction: What Device(s) to Choose in a Patient With NSTE-ACS?

Why Triple Therapy? Rationale and Potential Role for LAA Closure in the PCI Patient

Case Conclusion: How Did We Treat Our Patient?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content